CurrentEndo
Get Weekly

CurrentEndo coverage · page 9 of 55

Diabetes, Obesity and Metabolism

Briefs 321–360 of 2,200 CurrentEndo has covered from this journal, newest publication first

Latest from Diabetes, Obesity and Metabolism

All coverage, newest first

  1. Diabetes Obes Metab

    Glycemic Normalization Immediately Following Vertical Sleeve Gastrectomy in Adolescents With Type 2 Diabetes From the ST 2 OMP Study

    Cohort studyT2D & other

  2. Diabetes Obes Metab

    Incidence and Associated Factors of Hypertension and Dyslipidemia Improvement in People With Type 2 Diabetes Remission: A Multicenter Real‐World Retrospective Cohort Study (JDDM84)

    Cohort studyT2D & other

  3. Diabetes Obes Metab

    Investigating the Incremental Cost and Utilization Burden of Obstructive Sleep Apnea in Overweight to Severely Obese Patients

    Cohort studyObesity

  4. Diabetes Obes Metab

    Optic Ischaemic Neuropathy in Incretin‐Based Therapy: A Comparative Analysis of Real‐World Safety Data

    Research articleT2D & other

  5. Diabetes Obes Metab

    Perioperative Desaturation and Postoperative Nausea or Vomiting Requiring Antiemetic Administration in Glucagon‐Like Peptide‐1 Receptor Agonist Users Undergoing Ambulatory Ophthalmic Surgery Under Mild‐To‐Moderate Sedation: A Large Retrospective Cohort Study

    Cohort studyT2D & other

  6. Diabetes Obes Metab

    Risk of Age‐Related Ocular Diseases in Non‐Diabetic Adults With Obesity Using Glucagon‐Like Peptide 1 Receptor Agonists

    Cohort studyObesity

  7. Diabetes Obes Metab

    Associations of PM 2 .5 and Its Constituents With the Dynamic and Accelerated Progression of Cardiovascular‐Kidney‐Metabolic Syndrome: The Gold‐Health Cohort

    Cohort studyLipids & liver

  8. Diabetes Obes Metab

    Associations of Fasting Glucagon and the Glucagon–Alanine Index With Hepatic Steatosis and Liver Stiffness in Japanese Individuals With Type 2 Diabetes

    Cross-sectional studyT2D & other

  9. Diabetes Obes Metab

    Association of Post‐Oral Glucose Tolerance Test Hypoglycaemia With Clinical Features, Incident Diabetes and Mortality in the Di@bet.es Cohort

    Cohort studyT2D & other

  10. Diabetes Obes Metab

    Comparative Effects of Emerging Lp(a)‐Lowering Agents and PCSK9 ‐Directed Therapies on Lipoprotein(a): A Network Meta‐Analysis of Randomised Clinical Trials

    Meta-analysisLipids & liver

  11. Diabetes Obes Metab

    Glucagon‐Like Peptide‐1 Based Therapies and the Risk of Severe Gastrointestinal Motility Adverse Events: A Cohort Study

    Cohort studyT2D & other

  12. Diabetes Obes Metab

    Molecular Signature of Prediabetes With High‐Risk of Diabetes Revealed by Deep Plasma Proteome

    Cohort studyT2D & other

  13. Diabetes Obes Metab

    Multi‐Parametric Magnetic Resonance Imaging to Assess Empagliflozin Effect on the Kidneys in People With Type 2 Diabetes Mellitus: A Pilot Clinical Trial

    Randomized controlled trialT2D & other

  14. Diabetes Obes Metab

    Projecting the Macroeconomic Burden of Type 2 Diabetes Mellitus Attributable to High Body‐Mass Index in Southeast Asia: A Bayesian Productivity‐Adjusted Life Years Approach Based on Global Burden of Diseases 2023

    Cohort studyT2D & other

  15. Diabetes Obes Metab

    Trends in Second‐Line Initiations and Treatment Outcomes Across Age and Frailty Groups in People With Type 2 Diabetes: UK Population‐Based Study, 2019–2024

    Cohort studyT2D & other

  16. Diabetes Obes Metab

    Chronic Kidney Disease in Patients With Type 2 Diabetes Mellitus: A Cross‐Sectional Population‐Based Study

    Cross-sectional studyComplications

  17. Diabetes Obes Metab

    Cost‐Effectiveness of NT ‐ proBNP –Guided Cardiovascular Screening in Chinese Adults With Type 2 Diabetes: Real‐World Evidence From the Hong Kong Diabetes Biobank

    Cohort studyT2D & other

  18. Diabetes Obes Metab

    Empagliflozin Versus Dapagliflozin and Urogenital Adverse Events in Type 2 Diabetes: A Target Trial Emulation

    Cohort studyT2D & other

  19. Diabetes Obes Metab

    Heterogeneity of Treatment Effects Across Nine Glucose‐Lowering Drug Classes in Type 2 Diabetes: Extension of the LEGEND ‐ T2DM Network Study

    Cohort studyT2D & other

  20. Diabetes Obes Metab

    Intragastric Balloon Treatment Enhances Weight Maintenance Adjunct to Low‐Energy Diet and Group‐Based Cognitive Behavioural Therapy: A Randomized Controlled Trial

    Randomized controlled trialObesity

  21. Diabetes Obes Metab

    Short‐Term Combined Treatment With Tirzepatide and Metformin for Overweight/Obese Chinese Women With Polycystic Ovary Syndrome: A Prospective, Open‐Label, Randomised Controlled Trial

    Randomized controlled trialObesity

  22. Diabetes Obes Metab

    Insulin Sensitivity and Beta Cell Function With Macupatide Alone or With Dulaglutide in Type 2 Diabetes: A Phase 1b, Randomised Controlled Trial

    Randomized controlled trialT2D & other

  23. Diabetes Obes Metab

    Acute GIP and GLP ‐1 Administration Exerts Differential Metabolic Effects in Totally Pancreatectomised Individuals

    Randomized controlled trialT2D & other

  24. Diabetes Obes Metab

    Associations of Changes in Weight and Relative Fat Mass With All‐Cause and Cardiovascular Disease Mortality Among Older Community‐Dwellers in Guangzhou, China

    Cohort studyObesity

  25. Diabetes Obes Metab

    Cardiorenal Safety and Efficacy of Sotagliflozin: A Stratified Meta‐Analysis by Diabetes Type and Dosage

    Meta-analysisComplications

  26. Diabetes Obes Metab

    Efficacy and Safety of Once‐Weekly and Once‐Daily Basal Insulins in Type 1 Diabetes Mellitus: A Systematic Review and Network Meta‐Analysis of Clinical Trials

    Meta-analysisT1D

  27. Diabetes Obes Metab

    Glycaemic Control by Sociodemographic Factors in Adults With Type 1 Diabetes in England: Trends From 2007–2008 to 2023–2024

    Cross-sectional studyT1D

  28. Diabetes Obes Metab

    Greater Glycaemic Responses to Bodyweight Change in South Asians Than White Europeans at High Risk of Type 2 Diabetes

    Secondary analysisT2D & other

  29. Diabetes Obes Metab

    Identification of Frailty Subtypes in A frican A merican Adults With and Without Type 2 Diabetes: A Latent Class Analysis From the J ackson H eart S tudy

    Cross-sectional studyT2D & other

  30. Diabetes Obes Metab

    Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population‐Adjusted Indirect Treatment Comparison

    Meta-analysisObesity

  31. Diabetes Obes Metab

    Proteomic Profiling Captures Residual Cardiovascular Risk Beyond the PREVENT Model in Individuals With Cardiovascular–Kidney–Metabolic Syndrome Stages 2–3

    Diagnostic or prognostic study

  32. Diabetes Obes Metab

    Semaglutide 25 mg Oral Versus Semaglutide 2.4 mg Injectable: An Indirect Treatment Comparison of Weight Loss Outcomes

    Research articleObesity

  33. Diabetes Obes Metab

    Adding Finerenone to SGLT2 Inhibitors and Long‐Term Kidney Outcomes in Diabetic Kidney Disease

    Cohort studyComplications

  34. Diabetes Obes Metab

    Cardiovascular Disease Risk Prediction in Patients With Metabolic Dysfunction‐Associated Steatohepatitis

    Cohort studyLipids & liver

  35. Diabetes Obes Metab

    Evaluation of the Safety, Efficacy and Pharmacokinetics of BGM0504 in Chinese Adults With Type 2 Diabetes: A Multicentre, Randomised, Controlled and Double‐Blind Phase II Trial

    Randomized controlled trialT2D & other

  36. Diabetes Obes Metab

    Impact of Sleeve Gastrectomy Versus Intensive Lifestyle Modifications With Obesity Management Medications on BMI Trajectory and Target Attainment: A Prospective Matched Cohort Study

    Cohort studyObesity

  37. Diabetes Obes Metab

    Semaglutide Injection in Indian Patients With Type 2 Diabetes Mellitus: A Randomised, Phase III , Active‐Controlled Study

    Randomized controlled trialT2D & other

  38. Diabetes Obes Metab

    Supporting Weight Management for Kidney Transplant Candidates in People With Obesity on Haemodialysis: The First National Survey of UK Kidney Healthcare Providers

    Cross-sectional studyObesity

  39. Diabetes Obes Metab

    Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE ‐ JP Trial

    Randomized controlled trialObesity

  40. Diabetes Obes Metab

    The Effect of Canagliflozin Dose on Renal and Cardiovascular Outcomes in Type 2 Diabetes and High Cardiovascular Risk

    Secondary analysisT2D & other

All 2,200 Briefs in ExploreShowing Briefs 321–360 of 2,200, newest first